Furkan Bahar/X
Aug 3, 2026, 12:30
Furkan Bahar: Thrombotic and Hemorrhagic Risk Profiles in Advanced Melanoma – Targeted vs Immune Combination Therapies
Furkan Bahar, Research Fellow at Dana Farber, shared a post on X about a recent article he and his colleagues co-authored, published in RPTH, adding:
“Excited to share our new paper, published in Research and Practice in Thrombosis and Haemostasis!
We compared VTE and bleeding risk between BRAF/MEK inhibitors and ipilimumab/nivolumab combination therapy in patients with advanced melanoma.”
Title: Venous Thromboembolism and Bleeding in Advanced Melanoma: A Propensity-Matched Cohort Analysis Comparing First-Line Immunotherapy and Targeted Therapy
Authors: Furkan Bahar, Lauren O’Loughlin, Soravis Osataphan, Hollis Viray, Reed E. Drews, Rushad Patell
Stay updated with Hemostasis Today.
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event
-
Sep 25, 2026, 05:47Omid Seidizadeh: Evolutionary Constraint and Population Variation Across Coagulation Genes
-
Sep 25, 2026, 05:40Gerald Bertrand: Presenting UMi-NGS Non-Invasive Foetal HPA Genotyping at DGTI 2026
-
Sep 25, 2026, 05:33Urge Congress to support the Sickle Cell Disease Comprehensive Care Act – ASH